LRA Applauds GSK on Positive Phase 3 Study of Benlysta® for Lupus Nephritis

The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week's New England Journal of Medicine, demonstrating that GSK's drug BenlystaR (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney.